Pirenzepine: Development discontinued

AC Immune discontinued development of ACI-91 after top-line data from a double-blind, placebo-controlled, German and Austrian Phase II trial in 63 patients with mild to

Read the full 250 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE